Lauryn S. Bracken

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Michaela Waibel, Vanessa S. Solomon, Deborah A. Knight et al. · Cell Reports · 2013 · 129 citations · Full text

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling

Steven Goossens, Enrico Radaelli, Odile Blanchet et al. · Nature Communications · 2015 · 87 citations · Full text

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Donya Moradi Manesh, Jad El‐Hoss, Kathryn Evans et al. · Blood · 2015 · 62 citations · Full text

Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Santi Suryani, Lauryn S. Bracken, Richard C. Harvey et al. · Molecular Cancer Therapeutics · 2014 · 54 citations · Full text

Hematological Malignancy, Tumor Biology, Medicine +13

An assessment of the transparency of contemporary technology education research employing interview-based methodologies

Jeffrey Buckley, Latif Adams, Ifeoluwapo Aribilola et al. · International Journal of Technology and Design Education · 2021 · 20 citations

Interview-based Methodologies, Education, Technology Assessment +4